Company Overview
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.22.
Recent Developments
- Dec 2025 Revenue of $67.48M (+25.2% YoY); net profit $-278.67M.
- Trailing 12 Months Year-on-year growth — revenue +29.5%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | 29.50% |
Stock Price Performance
| 1 Year: | +77.01% |
| 6 Months: | +19.45% |
| 3 Months: | +28.90% |
| 1 Month: | +26.86% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)57.60 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | KURA Kura Oncology, Inc. R2K | 11.24 | -3.36 | $997.82M | 0.00% | -48.86% | -124.74% | - | - |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 14.11M | 15.29M | 20.75M | 18.27M |
| Operating Income | -4.47K | -4.14K | -5.24K | -4.76K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -54.45M | -56.40M | -59.88M | -64.70M | -72.67M | -80.00M | -78.81M |
| Net Income | -6.14K | -5.77K | -6.89K | -6.43K | -4.48M | -5.58M | -6.09M | -6.63M | -6.66M | -6.93M | -7.53M | -7.82M | -9.33M | -14.60M | -14.74M | -15.01M | -16.10M | -13.94M | -14.94M | -16.39M | -17.86M | -19.21M | -20.49M | -23.77M | -30.69M | -33.66M | -33.37M | -32.45M | -34.77M | -35.50M | -34.07M | -37.17M | -38.60M | -49.52M | -50.84M | -54.40M | -57.43M | -66.12M | -74.12M | -73.33M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.51 | -0.50 | -0.49 | -0.52 | -0.53 | -0.50 | -0.53 | -0.50 | -0.59 | -0.59 | -0.63 | -0.66 | -0.75 | -0.85 | -0.83 |
| R&D Expense | - | - | - | - | 2.60M | 3.35M | 3.64M | - | - | - | - | - | - | - | - | - | - | 10.38M | 11.44M | 12.54M | - | 12.57M | 13.70M | 16.60M | 20.32M | 21.07M | 22.37M | 20.91M | 24.26M | 24.97M | 25.19M | 28.18M | 29.33M | 36.27M | 39.73M | 41.70M | 55.97M | 62.78M | 67.91M | 65.26M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 53.88M | 67.48M |
| Operating Income | - | - | - | -20.51K | -23.44K | -22.34K | -22.73K | -23.91K | - | - | - | - | - | - | - | -139.87M | -165.80M | -193.19M | -303.63M |
| Net Income | -14.98K | -33.62K | -20.00K | -22.39K | -27.04K | -27.32K | -28.61K | -30.73K | -22.62M | -27.56M | -35.43M | -60.45M | -63.14M | -89.62M | -130.47M | -135.84M | -152.63M | -173.98M | -278.67M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.69 | -1.97 | -2.03 | -2.08 | -2.02 | -3.18 |
| R&D Expense | - | - | - | - | - | - | - | - | - | - | 26.43M | 46.79M | 47.83M | 60.40M | 84.72M | 92.81M | 115.23M | 169.97M | 251.07M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Nov 2007 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Sep 2011 | Dec 2011 | Sep 2012 | Dec 2012 | Dec 2013 | Aug 2014 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | - | - | - | - | - | - | 8.30K | 9.07K | - | 1.38M | 87.26M | 69.82M | 95.85M | 182.38M | 241.97M | 647.21M | 534.05M | 456.31M | 448.94M | 760.16M | 738.36M |
| Total Equity | 0 | 35.02K | 1.40K | -18.60K | -40.99K | - | -68.03K | - | -95.35K | -123.96K | 0 | -3.43M | 82.10M | 56.88M | 79.86M | 160.99M | 218.78M | 610.90M | 506.61M | 420.28M | 397.27M | 413.64M | 174.13M |
| Cash & Equivalents | 0 | - | - | 11.14K | 26.90K | 6.16K | 4.22K | 5.59K | 4.80K | 6.57K | - | 1.12M | 15.44M | 9.72M | 11.43M | 16.12M | 26.14M | 325.49M | 90.67M | 51.80M | 37.32M | 224.46M | 149.10M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | 7.32M | 5.57M | 7.50M | 7.25M | 4.25M | - | 9.16M | 9.33M | 6.92M | 9.71M |
| Total Liabilities | - | - | - | - | - | - | - | - | 103.65K | 133.03K | - | 4.81M | 5.16M | 12.95M | 15.99M | 21.39M | 23.19M | 36.31M | 27.44M | 36.03M | 51.66M | 346.52M | 564.23M |
| Current Liabilities | - | - | - | - | 70.39K | - | 74.75K | - | 103.65K | - | - | 3.02M | 5.05M | 5.45M | 10.03M | 13.62M | 15.56M | 26.02M | 22.45M | 24.06M | 35.26M | 78.71M | 116.97M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -19.24K | -22.68K | -24.42K | -23.23K | -15.96K | - | -28.44M | -48.66M | -54.76M | -69.83M | -104.55M | -110.06M | -124.82M | 134.32M | -64.06M |
| Investing Cash Flow | - | - | - | - | - | - | -23.42M | -79.30M | -46.33M | -99.94M | -126.83M | 32.63M | 15.56M | -101.59M | -13.10M |
| Financing Cash Flow | 35.00K | 0 | 25.00K | 25.00K | 15.00K | - | 53.57M | 132.64M | 111.10M | 469.33M | -3.44M | 38.56M | 94.78M | 154.42M | 1.79M |
| Capital Expenditure | - | - | - | - | - | -64.00K | - | - | - | -2.17M | -1.15M | -626.00K | -168.00K | -472.00K | -6.64M |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | -72.00M | -105.70M | -110.69M | -124.99M | 133.84M | -70.70M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -358.5% | -449.9% |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -322.9% | -412.9% |
| ROE % | -42.8% | -2,401.6% | 107.5% | 54.6% | 39.7% | 28.6% | 23.1% | 0.9% | -27.6% | -48.5% | -44.4% | -37.5% | -28.9% | -14.7% | -25.8% | -32.3% | -38.4% | -42.1% | -160.0% |
| ROCE % | - | - | - | - | - | 23.4% | - | 1.5% | - | - | - | - | - | - | - | -32.4% | -40.1% | -28.4% | -48.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 10.86% | 9.64M | $105.43M |
| 2 | Suvretta Capital Management, LLC | 9.66% | 8.58M | $93.82M |
| 3 | BVF Inc. | 9.51% | 8.45M | $92.40M |
| 4 | State Street Corporation | 5.08% | 4.51M | $49.36M |
| 5 | Vanguard Capital Management LLC | 4.26% | 3.79M | $41.42M |
| 6 | Armistice Capital, LLC | 4.21% | 3.74M | $40.87M |
| 7 | Prosight Management, Lp | 3.78% | 3.36M | $36.72M |
| 8 | Deep Track Capital, Lp | 2.98% | 2.64M | $28.92M |
| 9 | AQR Capital Management, LLC | 2.39% | 2.12M | $23.24M |
| 10 | Geode Capital Management, LLC | 2.29% | 2.03M | $22.25M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for KURA
Why Did KURA Stock Jump 13% In Pre-Market Today? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxOempYT3VNQ0V1bTc1TDdCdzc2UW1sd1VoZ0ZRNWxDX2k1N1g0UUdaekk0dVBEaXpRY3lLbU1vcWtiVWN6Y2hybHVjdkg0VXJ2dVE2RUFlb1FybWNIcEFHQUNkaEczTmx3aGNZbmhIZlhId0w4LUYyQmxPMVVWNjhLQTNhR2FqOUZYMExrbE…
Long-term kidney cancer data from Kura's drug due July 24 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxNWG9nSmdSM2stNjNhbU9pUmdQWUJtNV8yOGVLUDh4MzRuSDBQdjM2Yk85Y3RiOVFtell3eGVFMS1nanl6X2pxay1TZHkyRm1odF9XdU9PMkZxMjQ2eTNrcHNpRkFVUEtMNDJuZXhETUdpSC04MGYxOEdHTnloR0JHdklxcEhWRWpmOWdTMX…
Kura Sushi's stock climbs after Trump investment - SeafoodSource
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxOQUhpdmpmMzEtZGVlLW4wZ0lWSV9tOGVnd1NnTzdZNzExdnlpOVhHcUlFd2tzMHNjUU9MZ2w4N0JkZWxITko1aUpUNW82cHRub0dGdnNVTUtmbElQV25jVUQ4ZXY2SmR3S2w3RkQ3WkxMX0tmd3U1aWJZZXA3SkdmTGhuLV9HU0ZZNmNvZ1…
DA Davidson cuts Kura Sushi stock price target on sales guidance - Investing.com
<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxQM2tDTFNYeE5rcVA0VEtwSGYyZF94aTlTVzJUVXh1TVlzakxDNVVrRVhsRWVoRWpRR3BQY3A3RndEX2dpYUwwMHpLNkN1dGh5Vm5VaEtIOFk1a2RGZjV3SE9GZ1NuMXJVZktEVnkwWFlOcnFEd19pMlR4dDVxcklnWGZDRE5fTnV6SWZ5cW…
$KURA stock is down 8% today. Here's what we see in our data. | KURA Stock News - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxOUVZxaFgtM2k0eG1kNjI0S2h0SU9xQkNrTHdWMVdKNlBVM01jb0tSSGp2ZGYxSHdkZDdLSF93dzFFQU5Vb0ZjR1RCOE1ZbTRxTXlaeHY0S3h1cTJReHpRdWpYaThnTF9fMzBCQkh3NFBwX0pZUVNQNW9vOTFDOVJMSDFGcXpHWHR1dXNKUW…
Kura Sushi (NASDAQ:KRUS) Misses Q2 CY2026 Revenue Estimates, Stock Drops - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxPQVdNcHNKYS1vRURIX1ZLNExqZnczZF9hS1N2YUFLNlo3eEs0TlEzb0lsQzZHUFd2cmhERkZ2Z05DME1ZSi0tRU9IbklVMFh1dEhBQURsdElwSk96Y25UanNaeURid1JwV1paZWNKbzNuTVZqRFNWQWxBSFRUS0poYXJ6bFY5T2xOOUFEZE…
KURA — Frequently Asked Questions
What is the current share price of Kura Oncology, Inc. (KURA)?
As of 2026-07-14 21:23 PDT, Kura Oncology, Inc. (KURA) trades at $11.24 on NasdaqGS. Its 52-week range is $5.54 to $12.14.
What is the market capitalisation of KURA?
Kura Oncology, Inc. (KURA) has a market capitalisation of $997.82M on NasdaqGS.
What is the P/E ratio of KURA?
KURA trades at a trailing price-to-earnings (P/E) ratio of -3.36. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 7.45.
What is the return on equity (ROE) of KURA?
KURA has a return on equity (ROE) of -124.74%. Its return on capital employed (ROCE) is -48.86%.
Is KURA a good stock to buy?
This page provides a data-driven analysis of Kura Oncology, Inc. (KURA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.